BATF2 antibody - middle region (ARP47712_P050)
- Known as:
- BATF2 (anti-) - middle region (ARP47712_P050)
- Catalog number:
- arp47712_p050
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Aviva Systems Biology
- Gene target:
- BATF2 antibody - middle region (ARP47712_P050)
Related genes to: BATF2 antibody - middle region (ARP47712_P050)
- Gene:
- BATF2 NIH gene
- Name:
- basic leucine zipper ATF-like transcription factor 2
- Previous symbol:
- -
- Synonyms:
- MGC20410
- Chromosome:
- 11q13.1
- Locus Type:
- gene with protein product
- Date approved:
- 2006-02-11
- Date modifiied:
- 2016-06-28
Related products to: BATF2 antibody - middle region (ARP47712_P050)
Related articles to: BATF2 antibody - middle region (ARP47712_P050)
- Astrocytes are increasingly recognized as key regulators of multiple sclerosis (MS) pathogenesis, known to actively influence neuroinflammation, blood-brain barrier integrity, leukocyte recruitment, glial scar formation, and tissue repair. Evidence from both MS and its animal models demonstrates substantial astrocyte heterogeneity, exerting either pathogenic or neuroprotective functions depending on the local microenvironment. In this review, we discuss the diverse roles of astrocytes in MS, with particular focus on signaling pathways that govern astrocyte responses during chronic neuroinflammation. We further explore the growing evidence that astrocytes within chronic active lesion cores are not merely passive structural cells, but instead may be involved in immune regulation, survival signaling, and tissue maintenance. Collectively, these findings support a revised view of astrocytes as regulators of lesion dynamics and CNS homeostasis during MS. A deeper understanding of astrocyte heterogeneity and the signaling networks that control astrocyte function may reveal novel therapeutic opportunities to limit neurodegeneration and disease progression. - Source: PubMed
Publication date: 2026/07/22
Tinkey Rachel ASmith Brandon CWilliams Jessica L - Accurate diagnosis and effective treatment response monitoring (TRM) remain major challenges in tuberculosis (TB) control. Most existing tools are sputum based, yet many patients are unable to produce sputum at diagnosis or during treatment. We evaluated blood-based host transcriptional markers (HTM) for active TB diagnosis and TRM. - Source: PubMed
Publication date: 2026/07/08
Nakiboneka RitahMargaritella NicolòNyirenda Tonney SWalbaum NatashaMusisi EmmanuelTionge SikweseNliwasa MarriottMsefula Chisomo LWilliamson DeborahSloan DerekSabiiti Wilber - Radiation-induced heart disease (RIHD) is a common complication of thoracic radiotherapy. Currently, no optimal radioprotective agent is widely available for RIHD treatment. Shenfu Decoction (SFD) has been used as a Traditional Chinese Medicine for thousands of years. Recent studies have shown that SFD can enhance cardiac function. However, the key bioactive compounds in SFD and their underlying mechanisms in RIHD remain unclear. - Source: PubMed
Publication date: 2026/05/06
Wang MengyangZhang LinxinLiu WeiSun JinghuiYu HuiHan XueWang ChunmeiYan ShuangCui XiaoliSun Haiming - Immune checkpoint inhibitors like pembrolizumab exhibit variable efficacy in metastatic gastric cancer (GC). This study aimed to identify molecular drivers of pembrolizumab response, explore mechanisms of immune checkpoint inhibitors (ICIs) efficacy, and develop a prognostic signature. Transcriptomic analysis of pembrolizumab-treated GC (TIGER database) identified 165 response-associated differentially expressed genes (DEGs). Functional annotation and single-cell RNA sequencing (scRNA-seq) data from the Gene Expression Omnibus (GEO) revealed that responder-upregulated genes (R-DEGs) were enriched in immune activation pathways and mainly localized to CD8 + T/NK cells. In contrast, non-responder-upregulated genes (D-DEGs) were linked to extracellular matrix (ECM) remodeling and mainly expressed in fibroblasts/endothelial cells. CellChat analysis demonstrated that key DEGs mediate immune-stromal crosstalk via MHC-I and collagen/laminin signaling. A prognostic signature (Lasso-StepCox[forward] Riskscore; LSR: APOD, APOH, BATF2, GJA1, MAGED1, SLC5A1, SLCO2A1, VWF, VCAN) was derived and validated in four independent GC cohorts from the GEO and Cancer Genome Atlas (TCGA) database. Multi-omics analyses showed that LSR-high tumors exhibited aggressive clinicopathological features, increased stromal components, reduced cytotoxic immune infiltration, diminished tumor mutational burden (TMB), and poorer prognosis. Immunohistochemistry (IHC) and spatial transcriptomics in GC showed that stromal VWF/VCAN expression correlates with reduced CD8⁺ T cell granzyme B expression, suggesting T cell dysfunction. High VWF expression in GC predicted poor survival, and a combined VWF/VCAN score showed enhanced prognostic stratification. This study highlights stromal-immune crosstalk as a driver of pembrolizumab resistance and provides a signature as a clinical tool for prognosis and personalized therapy in metastatic GC. - Source: PubMed
Publication date: 2026/04/23
Zhang FanZhang QingqingShao ShuaiLi XiaoboCheng YiCao XuYu XiaotangGao Zhengming - Crohn's disease (CD) is a chronic, idiopathic inflammatory bowel disease. Understanding the genetic and immunological basis of CD can lead to better therapeutic strategies. - Source: PubMed
Publication date: 2026/04/21
Zhang XinweiLiu LinXu WenyuLi GuangxinQin QiuZhang Jinan